Friday, July 31, 2015
Tigenix NV Expands pipeline and enters the cardiology field with clinical-stage company acquisition.
TiGenix acquires Coretherapix, a cell therapy company with an ongoing Phase II clinical trial of allogeneic cardiac stem cells in acute myocardial infarction (AMI).
Acquisition is expected to be closed on July 31, 2015.
reuters.com
